Juergens Christine, de Villiers Pierre J T, Moodley Keymanthri, Jayawardene Deepthi, Jansen Kathrin U, Scott Daniel A, Emini Emilio A, Gruber William C, Schmoele-Thoma Beate
Pfizer GmbH; Berlin, Germany.
University of Stellenbosch; Tygerberg, South Africa.
Hum Vaccin Immunother. 2014;10(5):1343-53. doi: 10.4161/hv.27998. Epub 2014 Feb 27.
This randomized open-label trial was designed to provide preliminary immunogenicity and safety data to support development of the pediatric 13-valent pneumococcal conjugate vaccine (PCV13) for adults. The aims were to: identify an age-appropriate PCV13 formulation, i.e., with (n = 309) or without (n = 304) aluminum phosphate (AlPO 4); compare the selected PCV13 formulation (n = 309) with 23-valent pneumococcal polysaccharide vaccine (PPSV23; n = 301); and, together with an extension study, assess sequential use of pneumococcal vaccines at 1-year intervals in adults aged ≥65 years (n = 105) not pre-vaccinated with PPSV23. Immune responses were measured by ELISA and opsonophagocytic activity assays 1 month postvaccination. Immunoglobulin G responses elicited by PCV13 with AlPO 4 and PCV13 without AlPO 4 were similar for the majority, and noninferior for all PCV13 serotypes. PCV13 with AlPO 4 was generally more reactogenic, with reactions mainly mild or moderate. Thus, PCV13 with AlPO 4 (hereafter PCV13) became the selected formulation. Immune responses to PCV13 were noninferior for all but one serotype and for most PCV13 serotypes superior to PPSV23. Vaccine sequence assessments showed that for PCV13/PPSV23, the initial PCV13 dose generally enhanced responses to a subsequent PPSV23 dose, compared with PPSV23 alone. For PCV13/PCV13, a second dose did not enhance the first dose response when given after 1 year. For PCV13/PPSV23/PCV13, priming with PCV13 (vaccination 1) did not protect against lower responses induced by PPSV23 to subsequent PCV13 (vaccination 3). In conclusion, the pediatric PCV13 formulation with AlPO 4 is well tolerated and immunogenic in adults, is generally more immunogenic than PPSV23, and subsequent vaccination with PPSV23 is possible if required.
这项随机开放标签试验旨在提供初步的免疫原性和安全性数据,以支持成人用13价肺炎球菌结合疫苗(PCV13)的研发。其目的是:确定适合成人的PCV13配方,即含磷酸铝(AlPO4;n = 309)或不含磷酸铝(n = 304)的配方;将选定的PCV13配方(n = 309)与23价肺炎球菌多糖疫苗(PPSV23;n = 301)进行比较;并与一项扩展研究一起,评估在未接种过PPSV23的≥65岁成人(n = 105)中,每隔1年序贯使用肺炎球菌疫苗的情况。在接种疫苗1个月后,通过ELISA和吞噬调理活性测定来测量免疫反应。含AlPO4的PCV13和不含AlPO4的PCV13引发的大多数免疫球蛋白G反应相似,且对所有PCV13血清型均无劣效性。含AlPO4的PCV13通常反应原性更强,反应主要为轻度或中度。因此,含AlPO4的PCV13(以下简称PCV13)成为选定的配方。除一种血清型外,PCV13对所有血清型的免疫反应均无劣效性,且大多数PCV13血清型的免疫反应优于PPSV23。疫苗序贯评估表明,对于PCV13/PPSV23,与单独使用PPSV23相比,初始PCV13剂量通常可增强对后续PPSV23剂量的反应。对于PCV13/PCV13,1年后接种第二剂时不会增强第一剂的反应。对于PCV13/PPSV23/PCV13,用PCV13(第1次接种)进行初免并不能预防PPSV23对后续PCV13(第3次接种)诱导的较低反应。总之,表示含AlPO4的儿科PCV13配方在成人中耐受性良好且具有免疫原性,通常比PPSV23更具免疫原性,如有需要,后续可接种PPSV23。